[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607996":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":41,"responsibleParty":46,"collaborators":48,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":41,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":41,"enrollmentInfo":64,"targetDuration":41,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":78,"whyStopped":41,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":41},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dual Antiplatelet Therapy","ACTIVE_COMPARATOR","DAPT (aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily) for 30 consecutive days",[13],"Drug: Dual Antiplatelet (DAPT) Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Rivaroxaban","EXPERIMENTAL","Rivaroxaban (2.5 mg twice daily) plus aspirin 100 mg daily plus clopidogrel 75 mg daily for 30 days",[19],"Drug: Rivaroxaban",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dual Antiplatelet (DAPT) Therapy","aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days",[9],[27],"DAPT",{"type":22,"name":15,"description":17,"armGroupLabels":29,"otherNames":30},[15],[31],"Rivaroxaban + Aspirin + Clopidogrel",[33],{"name":34,"affiliation":5,"role":35},"Jun Jiang, Doctor","PRINCIPAL_INVESTIGATOR",[37,43],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Heyang Wang","CONTACT","86 571 87783721",null,"whysmmu@163.com",{"name":44,"role":39,"phone":41,"phoneExt":41,"email":45},"Guoyong Liu","283668235@qq.com",{"type":47,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR",[49,51,53],{"name":50,"class":6},"Affiliated Hospital of Jiaxing University",{"name":52,"class":6},"The Second Affiliated Hospital of Jiaxing University",{"name":54,"class":6},"Wenzhou People's Hospital","100607996","phase-4-rivaroxaban-for-slow-coronary-flow-after-pci-in-stemi-100607996",false,"NCT07195812","Rivaroxaban for Slow Coronary Flow After PCI in STEMI","Evaluation of the Efficacy and Safety of Rivaroxaban in Improving Slow Coronary Flow After Percutaneous Coronary Intervention in STEMI Patients: A Multicenter, Prospective,Randomized, Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender;\n* Patients with ST-segment elevation myocardial infarction (STEMI) (meeting the diagnostic criteria of the 2019 Chinese \"Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction\");\n* Patients undergoing percutaneous coronary intervention (PCI);\n* Patients with slow flow after PCI (TIMI flow grade \\> 0 but \\\u003C 3);\n* Signed informed consent form and willingness to comply with follow-up.\n\nExclusion Criteria:\n\n* Presence of malignant tumors or diseases with a life expectancy of less than 1 year;\n* Coagulation disorders, diagnosed or suspected hematological diseases (excluding mild or moderate anemia);\n* Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL); history of severe gastrointestinal diseases or peptic ulcers; active bleeding within the past 3 months or major surgery history; history of intracranial hemorrhage or intracranial aneurysm;\n* History of cerebral hemorrhage or ischemic stroke within the past 6 months;\n* Patients with cardiogenic shock; systemic infections or immune system diseases; confirmed, highly suspected, or unable to rule out aortic dissection; severe uncontrolled hypertension (systolic blood pressure \\> 180 mmHg and\u002For diastolic blood pressure \\> 110 mmHg);\n* Current use of rivaroxaban or requiring long-term anticoagulation therapy (e.g., atrial fibrillation);\n* Patients with renal insufficiency (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m²) or hepatic insufficiency (Child-Pugh Class B or C);\n* Lactating or pregnant women, or women of childbearing potential unable to use effective contraception during the study period;\n* Patients with any contraindications or allergies to rivaroxaban, aspirin, clopidogrel, or ticagrelor;\n* Participation in other clinical trials within the past 3 months;\n* Other conditions deemed unsuitable for participation by the investigator.","ALL","18 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban. The main questions it aims to answer are:\n\nDoes drug Rivaroxaban Reduce the Corrected TIMI Frame Count (cTFC) in 1 Week After PCI ?\n\nResearchers will compare Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) to Dual Antiplatelet Therapy to see if drug Combination therapy with rivaroxaban, aspirin works to treat Slow Flow in STEMI Patients After PCI.\n\nParticipants will:\n\nTake drug Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) or Dual Antiplatelet Therapy every day for 1 months.\n\nVisit the clinic in 7 days、30 days and 365 days for checkups and tests.",[72,73],"ST Elevation Myocardial Infarction","No-Reflow Phenomenon",[15,72,75,73,76,77],"Slow Coronary Flow","Antiplatelet Therapy","Percutaneous Coronary Intervention","NOT_YET_RECRUITING","2025-09-25",{"date":81,"type":82},"2025-09-29","ACTUAL",{"date":84,"type":66},"2025-10",{"date":86,"type":66},"2028-05",{"name":5,"class":6}]